
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Keywords: عارضه جانبی یا عوارض جانبی; Certolizumab Pegol; Crohn's Disease; Anti-Tumor Necrosis Factor α; AE; adverse event; anti-dsDNA; anti-double-stranded DNA antibodies; ANAs; antinuclear antibodies; CDAI; Crohn's Disease Activity Index; HBI; Harvey-Bradshaw Index; PRECiSE; PEGylate